AUTHOR

Dr Mike Tubbs

For decades, Dr Mike Tubbs worked on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing. Knowledge which gave him a unique perspective on the stock markets.

Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development.

Visit/519240/secret-sauce-the-key-to-serial-innovation-and-profit-growth
Share tips

Secret sauce: the key to serial innovation and profit growth

Why do some companies fizzle out and fade away while others build on a strong start? Dr Mike Tubbs looks at the key factors behind sustainable success…
5 Dec 2019
Visit/515752/stocks-that-offer-two-sectors-for-the-price-of-one
Share tips

Stocks that offer two sectors for the price of one

There are several excellent companies that dabble in two very different markets. Dr Mike Tubbs highlights the ones worth considering now.
26 Sep 2019
Visit/511814/how-stem-cells-are-changing-the-face-of-medicine
Share tips

How stem cells are changing the face of medicine

We have only just started getting to grips with the vast life-saving potential of stem cells, the basic building blocks of the body. Dr Mike Tubbs exp…
26 Jul 2019
Visit/509295/engineering-profits-the-british-industrial-champions-to-buy-now
Share tips

Engineering profits: the British industrial champions to buy now

Move over, Germany and Sweden. There are several world-class UK engineers in profitable niches supplying a vast array of industries with vital equipme…
20 Jun 2019
Advertisement
Visit/508385/swedish-engineer-hexagon-is-in-excellent-shape
Share tips

Swedish engineer Hexagon is in excellent shape

This Swedish engineer has been overshadowed by bigger local peers, but is well worth a look
12 Jun 2019
Visit/506557/look-for-profits-with-regeneron
Features

Look for profits with Regeneron

Regeneron, a US biotech company, specialises in treating eye diseases. But it’s far from a one-trick pony.
15 May 2019
Visit/506176/where-to-find-and-how-to-invest-in-founder-managed-firms
Share tips

Where to find and how to invest in founder-managed firms

Companies that are set up and then run by the same person for a long time tend to be lucrative investments. Dr Mike Tubbs explains why, how to find fo…
2 May 2019
Visit/504975/diploma-qualifies-for-your-portfolio
Share tips

Diploma qualifies for your portfolio

This British mid-cap is a successful global player with plenty of room for expansion, says Dr Mike Tubbs.
16 Apr 2019
Visit/504470/immunotherapy-new-hope-in-the-battle-against-cancer
Share tips

Immunotherapy: new hope in the battle against cancer

Immunotherapy is a burgeoning sector that heralds a breakthrough against the world’s second-most deadly disease. Dr Mike Tubbs explains how investors …
4 Apr 2019
Advertisement
Visit/503620/alexion-a-rare-opportunity-in-biotech
Share tips

Alexion: a rare opportunity in biotech

Alexion focuses on diseases that affect only a tiny proportion of the population – a lucrative niche.
3 Apr 2019
Advertisement
Visit/502730/illumina-shedding-light-on-genetics
Share tips

Illumina: shedding light on genetics

Illumina, the genome sequencing specialist, is a leader in a thriving market. Long-term investors should buy now, says Mike Tubbs.
6 Mar 2019
Visit/501790/rd-the-key-to-long-term-sales-and-profit-growth
Stock markets

R&D: the key to long-term sales and profit growth

Companies that spend heavily on research and development (R&D) greatly improve their long-term odds. Dr Mike Tubbs explains what to look out for – and…
7 Feb 2019
Visit/501067/the-strong-and-stable-stocks-offering-a-reliable-income
Stock markets

The strong and stable stocks offering a reliable income

Companies with a consistent record of rising payouts look especially attractive at present. Dr Mike Tubbs introduces his favourite “dividend aristocra…
24 Jan 2019
Visit/499401/profit-from-renishaws-precision
Share tips

Profit from Renishaw’s precision

Few people have heard of Renishaw, but its products and prospects are excellent, says Mike Tubbs.
14 Dec 2018
Visit/497963/salesforce-software-service-with-a-smile
Stocks and shares

Salesforce: software service with a smile

Salesforce, one of the world’s top software companies, has a bright future and is currently on sale.
16 Nov 2018
Visit/496754/profits-in-the-pipeline
Share tips

Profits in the pipeline

Shares in German biotech MorphoSys firm could double as the royalties start to roll in, says Mike Tubbs.
19 Oct 2018
Advertisement
Visit/496376/the-british-software-sector-stars-tech-stocks-to-buy-now
Share tips

The British software sector stars investors should buy now

You might not think of the UK as a market full of promising tech stocks. But our small- and medium-sized companies are punching above their weight, sa…
11 Oct 2018
Visit/494414/a-memorable-day-for-biogen-investors
Share tips

A memorable day for Biogen investors

Biotech company Biogen’s promising treatment for the most common cause of dementia has just cleared a key hurdle.
7 Sep 2018
Advertisement
Visit/493699/protect-your-profits-buy-firms-with-deep-and-wide-moats
Share tips

Protect your profits – buy firms with deep and wide moats

Firms with strong brands, superior products or that exploit network effects are hard for competitors to keep up with. That means big profits for their…
23 Aug 2018
Visit/492103/rws-translating-tech-into-profits
Share tips

RWS: translating tech into profits

RWS is a “picks-and-shovels” play for the technology sector, and boasts an excellent record, says Mike Tubbs.
27 Jul 2018
Visit/491453/inventing-in-university-spin-outs-companies
Share tips

The fledgling industries emerging from our universities

Science and engineering departments are innovation incubators, and regularly launch companies involved in a wide range of exciting new fields. Dr Mike…
13 Jul 2018
Visit/490448/halma-a-matchless-record-of-dividends
Features

Halma: a matchless record of dividends

Safety specialist Halma capped its remarkable run by entering the FTSE 100 – but more will come.
22 Jun 2018
Advertisement
Visit/488724/how-asml-is-profiting-from-moores-law
Share tips

How ASML is profiting from Moore’s law

ASML’s cutting-edge technology will capitalise on the growing demand for computer chips, says Mike Tubbs.
25 May 2018
Visit/488297/picks-and-shovels-investments
Share tips

Want to profit from a gold rush? Invest in the picks and shovels

Investing in a booming industry can be a risky business – only a lucky few will strike gold and produce the hot products of the future. There’s a much…
17 May 2018
Visit/486743/genome-the-pharmas-making-pills-tailored-to-your-genes
Economy

The pharmas making pills tailored to your genes

Reading your genome is becoming easier and cheaper. That makes it possible to figure out which medicines will work for you. Dr Mike Tubbs picks the co…
19 Apr 2018
Visit/485347/how-to-spot-tomorrows-big-stocks-today
Share tips

How to spot tomorrow’s big stocks today

Technological advances have transformed our day-to-day lives – and made fortunes for sharp-eyed investors. But how do you spot future innovators? Dr M…
23 Mar 2018
Visit/480542/firms-turning-research-development-into-profits
Features

Superheroes of science: the firms turning research into profits

Companies that spend a lot on research are promising candidates for super-charged growth. But how can you tell which ones are wasting their money? Dr …
25 Jan 2018
Advertisement
Visit/477909/how-to-invest-in-biotech-stocks-alzheimers-parkinsons-ms
Share tips

How to invest in the next big medical breakthrough

There is currently no cure for MS, Alzheimer’s and Parkinson’s diseases but research gallops on. There will be big rewards for the first drug company …
7 Dec 2017
Visit/473733/how-to-invest-in-the-fight-against-cancer
Share tips

How to invest in the fight against cancer

A new generation of anti-cancer drugs looks promising. There are four main ways to invest, with varying levels of risk. Dr Michael Tubbs explains.
29 Sep 2017